Kaplan-Meier Overall Survival Analysis for Primary Gliosarcoma versus Glioblastoma
A. mOS for primary gliosarcoma (n=22) versus GBM (n=451) (11.0 versus 14.8 months, log-rank p=NS). B. mOS among patients treated with temozolomide-based chemoradiotherapy (11.0 months GSM, n=14 versus 17.3 months GBM, n=256) (log-rank p=0.006)